| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/ANA.21380 |
| P932 | PMC publication ID | 3850281 |
| P698 | PubMed publication ID | 18571778 |
| P5875 | ResearchGate publication ID | 227714648 |
| P4011 | Semantic Scholar paper ID | 767d64682c1ec3f4a33c6d7b57c08db03881a75d |
| P50 | author | William Langston | Q8014309 |
| Katrina Gwinn | Q30501410 | ||
| Matthew J. Farrer | Q37380292 | ||
| Julia Fuchs | Q48931838 | ||
| Adam Braithwaite | Q57023304 | ||
| Kenya Nishioka | Q57554542 | ||
| Lisa Skipper | Q58001133 | ||
| Marie-Christine Chartier-Harlin | Q58238824 | ||
| Frank A Middleton | Q60976752 | ||
| Charles H Adler | Q64768286 | ||
| Nobutaka Hattori | Q64780524 | ||
| Thomas Gasser | Q64856147 | ||
| Owen A. Ross | Q67167640 | ||
| M M Hulihan | Q67211187 | ||
| J Kachergus | Q67211189 | ||
| Demetrius M. Maraganore | Q67217419 | ||
| L. Larvor | Q67385291 | ||
| Nilsson C | Q67385294 | ||
| P2860 | cites work | High-resolution whole-genome association study of Parkinson disease. | Q24535861 |
| Global variation in copy number in the human genome | Q24658083 | ||
| alpha-Synuclein locus triplication causes Parkinson's disease | Q27860533 | ||
| Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications | Q28241852 | ||
| The wide spectrum of spinocerebellar ataxias (SCAs) | Q28250912 | ||
| APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy | Q28288090 | ||
| Whole-genome analysis of Alu repeat elements reveals complex evolutionary history | Q28770097 | ||
| Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data | Q28943545 | ||
| VISTA: computational tools for comparative genomics | Q29547708 | ||
| Alpha-synuclein locus duplication as a cause of familial Parkinson's disease | Q29614762 | ||
| Alu repeats and human genomic diversity | Q29618341 | ||
| dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data | Q30899629 | ||
| Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP. | Q30978581 | ||
| Alterations of tumor suppressor and tumor-related genes in the development and progression of gastric cancer | Q33788100 | ||
| An Alu Transposition Model for the Origin and Expansion of Human Segmental Duplications | Q33906041 | ||
| An autosomal dominant, qualitative platelet disorder associated with multimerin deficiency, abnormalities in platelet factor V, thrombospondin, von Willebrand factor, and fibrinogen and an epinephrine aggregation defect. | Q34382869 | ||
| A comprehensive analysis of common copy-number variations in the human genome | Q35616521 | ||
| Genetics of Parkinson disease: paradigm shifts and future prospects. | Q36423921 | ||
| Parkinson's disease: the genetics of a heterogeneous disorder | Q36516918 | ||
| Hereditary form of parkinsonism—dementia | Q39116097 | ||
| Genome-wide SNP assay reveals structural genomic variation, extended homozygosity and cell-line induced alterations in normal individuals | Q40206193 | ||
| High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines | Q40572619 | ||
| Effect of allelic variation at the NACP-Rep1 repeat upstream of the alpha-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system | Q40761847 | ||
| Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation | Q42501526 | ||
| Alpha-synuclein missense and multiplication mutations in autosomal dominant Parkinson's disease | Q45016370 | ||
| SNCA multiplication is not a common cause of Parkinson disease or dementia with Lewy bodies. | Q45030508 | ||
| Alpha synuclein promoter and risk of Parkinson's disease: microsatellite and allelic size variability | Q47174355 | ||
| Deletion of multimerin-1 in alpha-synuclein-deficient mice | Q47395628 | ||
| Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication | Q48298527 | ||
| The ups and downs of alpha-synuclein mRNA expression | Q48375102 | ||
| Unexpected rescue of alpha-synuclein and multimerin1 deletion in C57BL/6JOlaHsd mice by beta-adducin knockout | Q48588384 | ||
| Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms | Q48846656 | ||
| Multiplication of the alpha-synuclein gene is not a common disease mechanism in Lewy body disease | Q49139527 | ||
| alpha-Synuclein gene duplication is present in sporadic Parkinson disease | Q53473267 | ||
| Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. | Q54626622 | ||
| alpha-synuclein gene haplotypes are associated with Parkinson's disease | Q57905836 | ||
| Collaborative Analysis of α-Synuclein Gene Promoter Variability and Parkinson Disease | Q57977634 | ||
| Genomewide SNP assay reveals mutations underlying Parkinson disease | Q60532590 | ||
| Increased susceptibility to sporadic Parkinson's disease by a certain combined alpha-synuclein/apolipoprotein E genotype | Q64862724 | ||
| Clinicopathologic study of a SNCA gene duplication patient with Parkinson disease and dementia | Q80493033 | ||
| Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease | Q80794093 | ||
| Loss of epigenetic control of synuclein-gamma gene as a molecular indicator of metastasis in a wide range of human cancers | Q81158739 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Parkinson's disease | Q11085 |
| Synuclein | Q24767155 | ||
| P304 | page(s) | 743-750 | |
| P577 | publication date | 2008-06-01 | |
| P1433 | published in | Annals of Neurology | Q564414 |
| P1476 | title | Genomic investigation of alpha-synuclein multiplication and parkinsonism | |
| P478 | volume | 63 |
| Q30628518 | A 6.4 Mb duplication of the α-synuclein locus causing frontotemporal dementia and Parkinsonism: phenotype-genotype correlations |
| Q60960028 | A Meta-Analysis of α-Synuclein Multiplication in Familial Parkinsonism |
| Q39450010 | A Prognostic View on the Application of Individualized Genomics in Parkinson’s Disease |
| Q43737132 | A novel X-linked disorder with developmental delay and autistic features |
| Q37309484 | A single nucleotide polymorphism in the 3'UTR of the SNCA gene encoding alpha-synuclein is a new potential susceptibility locus for Parkinson disease |
| Q97420592 | Ablating Tau Reduces Hyperexcitability and Moderates Electroencephalographic Slowing in Transgenic Mice Expressing A53T Human α-Synuclein |
| Q38564102 | Active immunization therapies for Parkinson's disease and multiple system atrophy |
| Q36191988 | Administration of electroconvulsive therapy for depression associated with deep brain stimulation in a patient with post-traumatic Parkinson's Disease: a case study |
| Q38121773 | Advances in the genetics of Parkinson disease |
| Q52568381 | Advancing Stem Cell Models of Alpha-Synuclein Gene Regulation in Neurodegenerative Disease |
| Q36242777 | Age-Associated ALU Element Instability in White Blood Cells Is Linked to Lower Survival in Elderly Adults: A Preliminary Cohort Study |
| Q36070618 | Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates |
| Q39722408 | Allelic imbalance of expression and epigenetic regulation within the alpha-synuclein wild-type and p.Ala53Thr alleles in Parkinson disease. |
| Q54159456 | Alpha-synuclein A53T mutation is not frequent on a sample of Brazilian Parkinson's disease patients |
| Q34330786 | Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. |
| Q57983231 | Alpha-synuclein polymorphisms are associated with Parkinson's disease in a Saskatchewan population |
| Q82253370 | Analysis of exon dosage using MLPA in South African Parkinson's disease patients |
| Q34717871 | Apoptosis signal-regulating kinase 1 modulates the phenotype of α-synuclein transgenic mice |
| Q37645620 | Association studies of sporadic Parkinson's disease in the genomic era. |
| Q37811463 | Autophagy and misfolded proteins in neurodegeneration |
| Q93351001 | Autophagy and the cell biology of age-related disease |
| Q34306431 | Autophagy as a stress-response and quality-control mechanism: implications for cell injury and human disease |
| Q37968082 | Autosomal dominant Parkinson's disease |
| Q36765217 | Autosomal dominant Parkinson's disease caused by SNCA duplications |
| Q33790301 | Behavioral Phenotyping and Pathological Indicators of Parkinson's Disease in C. elegans Models |
| Q33896664 | Biomarkers for cognitive impairment in Parkinson disease |
| Q37682748 | C. elegans as a model organism to investigate molecular pathways involved with Parkinson's disease. |
| Q64760301 | CCAAT/enhancer binding protein δ is a transcriptional repressor of α-synuclein |
| Q37040842 | Caudo‐rostral brain spreading of α‐synuclein through vagal connections |
| Q55048859 | Cellular and Molecular Basis of Neurodegeneration in Parkinson Disease. |
| Q42154902 | Characterization of a Novel Mutation in SLC1A1 Associated with Schizophrenia |
| Q37572904 | Common variant rs356182 near SNCA defines a Parkinson's disease endophenotype |
| Q88584638 | Copy Number Variation Disorders |
| Q33364337 | Copy number variability in Parkinson's disease: assembling the puzzle through a systems biology approach |
| Q37786653 | Copy number variation in Parkinson's disease |
| Q33917317 | Creation of a library of induced pluripotent stem cells from Parkinsonian patients. |
| Q90059541 | Critical Roles of Deubiquitinating Enzymes in the Nervous System and Neurodegenerative Disorders |
| Q37855127 | Cytoplasmic dynein in neurodegeneration |
| Q48348755 | Delay Discounting of Reward and Caudate Nucleus Volume in Individuals with α-Synuclein Gene Duplication before and after the Development of Parkinson’s Disease |
| Q90237254 | Demonstration of brain region-specific neuronal vulnerability in human iPSC-based model of familial Parkinson's disease |
| Q37181996 | Deubiquitinase Usp8 regulates α-synuclein clearance and modifies its toxicity in Lewy body disease. |
| Q37466137 | Dosage-dependent severity of the phenotype in patients with mental retardation due to a recurrent copy-number gain at Xq28 mediated by an unusual recombination. |
| Q38837604 | Early synaptic dysfunction in Parkinson's disease: Insights from animal models. |
| Q40441648 | Elevated Levels of α-Synuclein Oligomer in the Cerebrospinal Fluid of Drug-Naïve Patients with Parkinson's Disease |
| Q37706391 | Enhanced ubiquitin-dependent degradation by Nedd4 protects against α-synuclein accumulation and toxicity in animal models of Parkinson's disease. |
| Q38881221 | Epigenetic regulation in Parkinson's disease |
| Q34389030 | Evaluation of the role of SNCA variants in survival without neurological disease |
| Q28395854 | Examining the relationship between head trauma and neurodegenerative disease: A review of epidemiology, pathology and neuroimaging techniques |
| Q37295073 | Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human alpha-synuclein in transgenic mouse brain. |
| Q47288069 | Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons. |
| Q37810586 | Flexible Nets of Malleable Guardians: Intrinsically Disordered Chaperones in Neurodegenerative Diseases |
| Q35808359 | Fractalkine Signaling Regulates the Inflammatory Response in an α-Synuclein Model of Parkinson Disease. |
| Q34335126 | G51D α‐synuclein mutation causes a novel Parkinsonian–pyramidal syndrome |
| Q55209699 | Genetic fine-mapping of the Iowan SNCA gene triplication in a patient with Parkinson's disease. |
| Q33510936 | Genetic regulation of alpha-synuclein mRNA expression in various human brain tissues |
| Q37907930 | Genetic variability in SNCA and Parkinson's disease |
| Q38233866 | Genetics and genomics of Parkinson's disease |
| Q28077356 | Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance |
| Q26827825 | Genetics of Parkinson's disease |
| Q35094704 | Genetics of Vascular Dementia |
| Q34898429 | Gene–Environment Interactions in Parkinson's Disease: The Importance of Animal Modeling |
| Q51691934 | Glucose Metabolism and AMPK Signaling Regulate Dopaminergic Cell Death Induced by Gene (α-Synuclein)-Environment (Paraquat) Interactions |
| Q35726904 | Head injury, α-synuclein Rep1, and Parkinson's disease |
| Q36748956 | High expression of α-synuclein in damaged mitochondria with PLA2G6 dysfunction |
| Q38814888 | How close are we to individualized medicine for Parkinson's disease? |
| Q28115600 | Identification of TMEM230 mutations in familial Parkinson's disease |
| Q89900496 | In Vitro CRISPR/Cas9-Directed Gene Editing to Model LRRK2 G2019S Parkinson's Disease in Common Marmosets |
| Q27026407 | In sickness and in health: the role of TRAPP and associated proteins in disease |
| Q46252300 | In vivo models of alpha-synuclein transmission and propagation. |
| Q34860779 | Independent and joint effects of the MAPT and SNCA genes in Parkinson disease |
| Q51082143 | Interaction of LRRK2 and α-Synuclein in Parkinson's Disease |
| Q47972111 | Investigating ioflupane I123 injection and single photon emission tomography as an imaging biomarker for long-term sequelae following mild traumatic brain injury |
| Q47547717 | Long-lasting pathological consequences of overexpression-induced α-synuclein spreading in the rat brain |
| Q38038561 | Lysosome-dependent pathways as a unifying theme in Parkinson's disease. |
| Q41894807 | MHCII is required for α-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration |
| Q28078563 | Major influence of repetitive elements on disease-associated copy number variants (CNVs) |
| Q26772943 | Mechanism of Anti-α-Synuclein Immunotherapy |
| Q37634108 | Mechanism, prevalence, and more severe neuropathy phenotype of the Charcot-Marie-Tooth type 1A triplication |
| Q38488082 | Mechanisms of alpha-synuclein action on neurotransmission: cell-autonomous and non-cell autonomous role |
| Q22251063 | Missing pieces in the Parkinson's disease puzzle |
| Q48323464 | Modeling Parkinson's disease with induced pluripotent stem cells harboring α-synuclein mutations |
| Q38286574 | Models of α-synuclein aggregation in Parkinson's disease |
| Q37309838 | Molecular mechanisms of alpha-synuclein neurodegeneration |
| Q35699310 | Monoallelic expression of the human FOXP2 speech gene |
| Q34342813 | Mosaicism of alpha-synuclein gene rearrangements: report of two unrelated cases of early-onset parkinsonism |
| Q27027973 | Neuroimmunological Processes in Parkinson’s Disease and their Relation to α-Synuclein: Microglia as the Referee between Neuronal Processes and Peripheral Immunity |
| Q44603447 | New brain-specific beta-synuclein isoforms show expression ratio changes in Lewy body diseases. |
| Q48502440 | New developments in genetic rat models of Parkinson's disease |
| Q34267681 | Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease |
| Q37825631 | Parkinson's Disease Dementia and Potential Therapeutic Strategies |
| Q64111645 | Parkinson's disease age at onset genome-wide association study: Defining heritability, genetic loci, and α-synuclein mechanisms |
| Q36346542 | Parkinson's disease and α-synuclein expression |
| Q35692589 | Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus |
| Q48109944 | Parkinson's disease susceptibility variants and severity of Lewy body pathology |
| Q34140428 | Parkinson's disease: Exit toxins, enter genetics |
| Q22242870 | Parkinson's disease: from monogenic forms to genetic susceptibility factors |
| Q47575506 | Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease. |
| Q33939245 | Population-specific frequencies for LRRK2 susceptibility variants in the Genetic Epidemiology of Parkinson's Disease (GEO-PD) Consortium |
| Q35703154 | Positive symptoms of psychosis correlate with expression of ubiquitin proteasome genes in peripheral blood |
| Q34140991 | Postural instability/gait disturbance in Parkinson's disease has distinct subtypes: an exploratory analysis |
| Q39150857 | Pramipexole Reduces Phosphorylation of α-Synuclein at Serine-129 |
| Q37918059 | Proteostasis and Movement Disorders: Parkinson's Disease and Amyotrophic Lateral Sclerosis |
| Q30249553 | Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management |
| Q39681299 | Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells |
| Q33636374 | Rationale for therapeutic silencing of alpha-synuclein in Parkinson's disease |
| Q34995420 | Regulation of autophagy by mTOR-dependent and mTOR-independent pathways: autophagy dysfunction in neurodegenerative diseases and therapeutic application of autophagy enhancers. |
| Q47910797 | Relative contribution of simple mutations vs. copy number variations in five Parkinson disease genes in the Belgian population |
| Q26796241 | Relevance of chronic stress and the two faces of microglia in Parkinson's disease |
| Q89624613 | Replication-Based Rearrangements Are a Common Mechanism for SNCA Duplication in Parkinson's Disease |
| Q38650395 | Review: Parkinson's disease: from synaptic loss to connectome dysfunction. |
| Q28080047 | Role of microRNAs in the Regulation of α-Synuclein Expression: A Systematic Review |
| Q39188180 | Structural variants in SNCA gene and the implication to synucleinopathies |
| Q27310037 | Synucleins Antagonize Endoplasmic Reticulum Function to Modulate Dopamine Transporter Trafficking |
| Q59353556 | Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease |
| Q58726908 | The Role of TMEM230 Gene in Parkinson's Disease |
| Q34538444 | The effect of SNCA 3' region on the levels of SNCA-112 splicing variant |
| Q38139561 | The function of α-synuclein |
| Q34074501 | The genetic contributions of SNCA and LRRK2 genes to Lewy Body pathology in Alzheimer's disease |
| Q36626825 | The genetics of Parkinson's disease: Progress and therapeutic implications |
| Q41525066 | The impact of genetic research on our understanding of Parkinson's disease |
| Q38670012 | The implication of neuronimmunoendocrine (NIE) modulatory network in the pathophysiologic process of Parkinson's disease |
| Q45387129 | The many faces of alpha-synuclein mutations |
| Q99585801 | The mechanistic role of alpha-synuclein in the nucleus: impaired nuclear function caused by familial Parkinson's disease SNCA mutations |
| Q93075481 | The oral microbiome of early stage Parkinson's disease and its relationship with functional measures of motor and non-motor function |
| Q34537231 | The role of Galectin-3 in α-synuclein-induced microglial activation |
| Q64814697 | The role of de novo mutations in adult-onset neurodegenerative disorders. |
| Q26773443 | Unfolded Protein Response and Macroautophagy in Alzheimer's, Parkinson's and Prion Diseases |
| Q37004246 | Up-regulation of SNCA gene expression: implications to synucleinopathies |
| Q38092552 | Using viral-mediated gene delivery to model Parkinson's disease: Do nonhuman primate investigations expand our understanding? |
| Q39784491 | VPS41, a protein involved in lysosomal trafficking, is protective in Caenorhabditis elegans and mammalian cellular models of Parkinson's disease. |
| Q37968018 | Vaccination for Parkinson's disease |
| Q60956179 | overexpression disturbs hippocampal gene expression trajectories in midlife |
| Q34115757 | {alpha}-Synuclein gene duplication impairs reward learning |
| Q21090919 | α-Synuclein Genetic Variants Predict Faster Motor Symptom Progression in Idiopathic Parkinson Disease |
| Q38040282 | α-Synuclein elevation in human neurodegenerative diseases: experimental, pathogenetic, and therapeutic implications. |
| Q35005567 | α-Synuclein impairs macroautophagy: implications for Parkinson's disease. |
| Q39256792 | α-Synuclein nonhuman primate models of Parkinson's disease |
Search more.